- Mindset Pharma Inc. (MSET) has entered a research collaboration with the Centre for Addiction and Mental Health (CAMH)
- It will sponsor a preclinical study at CAMH for the psychedelic drug candidate, MSP-1014
- The drug is new and patented second generation psilocybin-like compound
- it expects to see changes in functional activity, learning, and memory
- Mindset Pharma Inc. (MSET) is down 2.94 per cent trading at $0.33 per share as of 12:33 p.m. ET
Mindset Pharma (MSET) has announced a research collaboration with the Centre for Addiction and Mental Health (CAMH), a psychiatric research hospital in Toronto.
Mindset stated it will sponsor a preclinical study at CAMH for the drug candidate, MSP-1014, a novel and patented second generation psilocybin-like compound that is being used for first-in-human studies alongside psilocybin.The study will look at how macro and micro doses of psychedelic compounds control these expressions in rats.
According to the company, it expects to see short- and long-term changes in functional activity, learning, and memory. These results could trigger the long-term behavioural changes associated with a psychedelic experience and develop insights into the degree of effects for MSP-1014 compared to psilocybin.
“Mindset’s drug discovery platform is built on a broad spectrum of high-quality scientific data generated in preclinical models… will profile and build our understanding of the observed superiority of our lead asset, MSP-1014, to psilocybin at the molecular level,” James Lanthier, CEO of Mindset, said.
Dr. Anh Dzung Lê, Senior Scientist and Head of Neurobiology at CAMH, will lead the study, supported by Dr. Douglas Funk, a project scientist in the same department.
“Given that by the time Canadians reach 40 years of age, one in two have – or have had – a mental illness, CAMH scientists and clinicians are dedicated to exploring treatment option that account for the unique needs of individual patients,” Dr. Anh Dzung Lê, said.
Mindset Pharma Inc. (MSET) is down 2.94 per cent trading at $0.33 per share as of 12:33 p.m. ET.
